What is Biomea Fusion, Inc. (BMEA) stock price today?

Biomea Fusion, Inc. (BMEA) is currently trading at $1.42, up 3.65% today.

What is BMEA P/E ratio?

Biomea Fusion, Inc.'s P/E ratio is -2.56. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BMEA return on equity (ROE)?

Biomea Fusion, Inc.'s return on equity (ROE) is -171.19%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Biomea Fusion, Inc.'s market cap?

Biomea Fusion, Inc. has a market capitalization of $102.67M.

NASDAQ · Biotechnology

Biomea Fusion, Inc. (BMEA) Stock

$1.42 +3.65% NASDAQ: BMEA Healthcare

Valuation

Metric	Value
Price	$1.42
Market Cap	$102.67M
P/E Ratio	-2.56
P/B Ratio	7.57
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$2.99
52-Week Low	$0.87
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-171.19%
ROA	-88.24%
ROCE	-220.02%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.07
Current Ratio	5.27

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-42.0M	$-84.0M	$-126.0M	$-144.0M	$-81.0M
Net Profit	$-42.0M	$-82.0M	$-117.0M	$-138.0M	$-62.0M
EPS	$-1.74	$-2.80	$-3.44	$-3.83	$-1.18
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$186.0M	$129.0M	$200.0M	$80.0M	$59.0M
Total Liabilities	$7.0M	$21.0M	$31.0M	$28.0M	$29.0M
Cash	$146.0M	$112.0M	$177.0M	$58.0M	$56.0M
Borrowings	$3.0M	$2.0M	$10.0M	$9.0M	$2.0M

Latest News

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study GlobeNewswire · Jun 5, 2026 Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity GlobeNewswire · Jun 3, 2026 Biomea Fusion to Participate at Upcoming Investor Conferences GlobeNewswire · May 12, 2026 Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire · May 11, 2026 Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions GlobeNewswire · May 5, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-35.0M	$-62.0M	$-97.0M	$-120.0M	$-70.0M
Investing Cash Flow	$-37.0M	$26.0M	$-6.0M	$-1.0M	$0
Financing Cash Flow	$0	$1.0M	$2.0M	$0	$0
Net Cash Flow	$84.0M	$-34.0M	$65.0M	$-119.0M	$-2.0M
Free Cash Flow	$-39.0M	$-63.0M	$-100.0M	$-120.0M	$-70.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-1.69
FCF Yield	-51.26%
Quick Ratio	3.47
Interest Coverage	0.00
Return 1Y	-29.49%
Return 3Y	-94.55%
Return 5Y	-90.81%

Ownership

Insiders Held7.17%

Institutions Held38.88%

Institutions Float Held41.88%

Institutional Holder	Shares	Report Date
FMR, LLC	8,813,359	2026-03-31
Vanguard Capital Management LLC	2,597,300	2026-03-31
Aisling Capital Management LP	2,048,757	2026-03-31
Renaissance Technologies, LLC	1,312,798	2026-03-31
Marshall Wace LLP	1,198,551	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Biomea Fusion, Inc.

Biomea Fusion, Inc. is led by CEO Michael J. Hitchcock, employs 79 people, headquartered in US, publicly traded since 2021.

Biomea Fusion, Inc. (BMEA) stock trades at $1.42 with a market capitalization of $102.67M. The stock is valued at a price-to-earnings (P/E) ratio of -2.56, price-to-book of 7.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.87 and $2.99, and currently trades 52.5% below its 52-week high.

On profitability, Biomea Fusion, Inc. generates a return on equity (ROE) of -171.19%, return on capital employed of -220.02%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides